NO20055143L - Doseringsformer innbefattende AG013736 - Google Patents

Doseringsformer innbefattende AG013736

Info

Publication number
NO20055143L
NO20055143L NO20055143A NO20055143A NO20055143L NO 20055143 L NO20055143 L NO 20055143L NO 20055143 A NO20055143 A NO 20055143A NO 20055143 A NO20055143 A NO 20055143A NO 20055143 L NO20055143 L NO 20055143L
Authority
NO
Norway
Prior art keywords
dosage forms
forms including
prodrugs
solvates
cancers
Prior art date
Application number
NO20055143A
Other languages
English (en)
Other versions
NO20055143D0 (no
Inventor
James Lawrence Freddo
Dana Hu-Lowe
Yazdi Kersi Pithavala
Heidi Marie Steinfeldt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20055143D0 publication Critical patent/NO20055143D0/no
Publication of NO20055143L publication Critical patent/NO20055143L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det tilveiebringes doseringsformer av en forbindelse med formel (1) eller farmasøytisk akseptable salter, solvater eller prodrugs derav. Det beskrives videre metoder for behandling av anormal cellevekst, som cancere, ved å administrere doseringsformen til et pattedyr.
NO20055143A 2003-04-03 2005-11-02 Doseringsformer innbefattende AG013736 NO20055143L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31
PCT/IB2004/000867 WO2004087152A1 (en) 2003-04-03 2004-03-17 Dosage forms comprising ag013736

Publications (2)

Publication Number Publication Date
NO20055143D0 NO20055143D0 (no) 2005-11-02
NO20055143L true NO20055143L (no) 2006-01-03

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055143A NO20055143L (no) 2003-04-03 2005-11-02 Doseringsformer innbefattende AG013736

Country Status (16)

Country Link
US (1) US20040224988A1 (no)
EP (1) EP1613320A1 (no)
JP (1) JP2006522087A (no)
KR (1) KR20050119671A (no)
AR (1) AR043822A1 (no)
AU (1) AU2004226586B2 (no)
BR (1) BRPI0409230A (no)
CA (1) CA2520932A1 (no)
MX (1) MXPA05009303A (no)
NL (1) NL1025873C2 (no)
NO (1) NO20055143L (no)
PA (1) PA8599701A1 (no)
RU (2) RU2341263C2 (no)
TW (1) TW200423933A (no)
UY (1) UY28255A1 (no)
WO (1) WO2004087152A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
MX2007005291A (es) * 2004-11-02 2007-07-19 Pfizer Metodos para preparar compuestos de indazol.
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
MX2009010761A (es) * 2007-04-05 2009-10-28 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
SG11201400145VA (en) 2011-09-30 2014-03-28 Pfizer Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
KR20140088556A (ko) 2011-11-11 2014-07-10 화이자 인코포레이티드 만성 골수성 백혈병을 치료하기 위한 n-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일설파닐]-벤즈아미드
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
MX2016010082A (es) 2014-02-04 2016-10-07 Pfizer Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
JP6414727B2 (ja) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 関節疾患の治療予防剤
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
IL278423B2 (en) 2015-02-26 2024-04-01 Merck Patent Gmbh Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
WO2016205277A1 (en) 2015-06-16 2016-12-22 Merck Patent Gmbh Pd-l1 antagonist combination treatments
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
AU2017339856A1 (en) 2016-10-06 2019-05-23 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) * 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (ja) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 光パワー計測システム並びにそのための端局及び中継器
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
RU2341263C2 (ru) 2008-12-20
PA8599701A1 (es) 2004-11-26
JP2006522087A (ja) 2006-09-28
EP1613320A1 (en) 2006-01-11
MXPA05009303A (es) 2005-10-05
AU2004226586A1 (en) 2004-10-14
RU2005128791A (ru) 2006-05-10
TW200423933A (en) 2004-11-16
NL1025873C2 (nl) 2006-02-14
UY28255A1 (es) 2004-11-30
CA2520932A1 (en) 2004-10-14
RU2008122358A (ru) 2009-12-10
NO20055143D0 (no) 2005-11-02
AU2004226586B2 (en) 2008-12-11
KR20050119671A (ko) 2005-12-21
NL1025873A1 (nl) 2004-10-05
US20040224988A1 (en) 2004-11-11
AR043822A1 (es) 2005-08-17
BRPI0409230A (pt) 2006-03-28
WO2004087152A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
NO20055143L (no) Doseringsformer innbefattende AG013736
NO20051303L (no) Nye benzoimidazolderivater nyttige som antiproliferative midler
NO20053483L (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20063382L (no) Nye kinolinderivater
NO20054852L (no) GFAT inhibitorer
ECSP055867A (es) Derivados de pirrolopirimidina
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
NO20050921L (no) Nye fysiologisk aktive substanser
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
NO20076254L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application